Logo image of ABSI

ABSCI CORP (ABSI) Stock Fundamental Analysis

NASDAQ:ABSI - Nasdaq - US00091E1091 - Common Stock - Currency: USD

2.66  0 (0%)

After market: 2.65 -0.01 (-0.38%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ABSI. ABSI was compared to 561 industry peers in the Biotechnology industry. ABSI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ABSI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ABSI had negative earnings in the past year.
In the past year ABSI has reported a negative cash flow from operations.
In the past 5 years ABSI always reported negative net income.
In the past 5 years ABSI always reported negative operating cash flow.
ABSI Yearly Net Income VS EBIT VS OCF VS FCFABSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ABSI has a Return On Assets of -48.27%. This is comparable to the rest of the industry: ABSI outperforms 47.95% of its industry peers.
ABSI has a Return On Equity of -57.56%. This is comparable to the rest of the industry: ABSI outperforms 59.71% of its industry peers.
Industry RankSector Rank
ROA -48.27%
ROE -57.56%
ROIC N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ABSI Yearly ROA, ROE, ROICABSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABSI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABSI Yearly Profit, Operating, Gross MarginsABSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

4

2. Health

2.1 Basic Checks

ABSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABSI has more shares outstanding than it did 1 year ago.
ABSI has more shares outstanding than it did 5 years ago.
ABSI has a better debt/assets ratio than last year.
ABSI Yearly Shares OutstandingABSI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ABSI Yearly Total Debt VS Total AssetsABSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ABSI has an Altman-Z score of 1.52. This is a bad value and indicates that ABSI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.52, ABSI is in the better half of the industry, outperforming 71.84% of the companies in the same industry.
ABSI has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ABSI has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1.52
ROIC/WACCN/A
WACC10.04%
ABSI Yearly LT Debt VS Equity VS FCFABSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.67 indicates that ABSI has no problem at all paying its short term obligations.
With a Current ratio value of 4.67, ABSI perfoms like the industry average, outperforming 51.69% of the companies in the same industry.
A Quick Ratio of 4.67 indicates that ABSI has no problem at all paying its short term obligations.
ABSI's Quick ratio of 4.67 is in line compared to the rest of the industry. ABSI outperforms 52.94% of its industry peers.
Industry RankSector Rank
Current Ratio 4.67
Quick Ratio 4.67
ABSI Yearly Current Assets VS Current LiabilitesABSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

ABSI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.96%, which is quite impressive.
ABSI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -20.71%.
Measured over the past years, ABSI shows a quite strong growth in Revenue. The Revenue has been growing by 17.09% on average per year.
EPS 1Y (TTM)20.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.55%
Revenue 1Y (TTM)-20.71%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%31.29%

3.2 Future

The Earnings Per Share is expected to grow by 5.12% on average over the next years.
ABSI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.38% yearly.
EPS Next Y5.36%
EPS Next 2Y10.18%
EPS Next 3Y11.42%
EPS Next 5Y5.12%
Revenue Next Year80.59%
Revenue Next 2Y89.71%
Revenue Next 3Y104.37%
Revenue Next 5Y63.38%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ABSI Yearly Revenue VS EstimatesABSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
ABSI Yearly EPS VS EstimatesABSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABSI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABSI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABSI Price Earnings VS Forward Price EarningsABSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABSI Per share dataABSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.18%
EPS Next 3Y11.42%

More info and screens

0

5. Dividend

5.1 Amount

ABSI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABSCI CORP

NASDAQ:ABSI (5/23/2025, 9:11:29 PM)

After market: 2.65 -0.01 (-0.38%)

2.66

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners64.09%
Inst Owner Change16.26%
Ins Owners7.68%
Ins Owner Change1.2%
Market Cap339.28M
Analysts82.67
Price Target9.31 (250%)
Short Float %20.41%
Short Ratio6.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.93%
Min EPS beat(2)-13.12%
Max EPS beat(2)-2.74%
EPS beat(4)0
Avg EPS beat(4)-7.05%
Min EPS beat(4)-13.12%
Max EPS beat(4)-1.74%
EPS beat(8)0
Avg EPS beat(8)-15.03%
EPS beat(12)1
Avg EPS beat(12)-10.38%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-34.09%
Min Revenue beat(2)-63.32%
Max Revenue beat(2)-4.87%
Revenue beat(4)0
Avg Revenue beat(4)-40.24%
Min Revenue beat(4)-63.32%
Max Revenue beat(4)-4.87%
Revenue beat(8)1
Avg Revenue beat(8)-39.29%
Revenue beat(12)2
Avg Revenue beat(12)-38.15%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.8%
PT rev (3m)5.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.2%
EPS NY rev (1m)3.05%
EPS NY rev (3m)-5.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-72.99%
Revenue NY rev (1m)-4.11%
Revenue NY rev (3m)-31.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 74.83
P/FCF N/A
P/OCF N/A
P/B 1.89
P/tB 2.53
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.04
BVpS1.4
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.27%
ROE -57.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.02%
Cap/Sales 8.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.67
Quick Ratio 4.67
Altman-Z 1.52
F-Score4
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)44.41%
Cap/Depr(5y)179.67%
Cap/Sales(3y)101.78%
Cap/Sales(5y)229.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.55%
EPS Next Y5.36%
EPS Next 2Y10.18%
EPS Next 3Y11.42%
EPS Next 5Y5.12%
Revenue 1Y (TTM)-20.71%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%31.29%
Revenue Next Year80.59%
Revenue Next 2Y89.71%
Revenue Next 3Y104.37%
Revenue Next 5Y63.38%
EBIT growth 1Y-14.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.3%
EBIT Next 3Y17.13%
EBIT Next 5YN/A
FCF growth 1Y-11.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.01%
OCF growth 3YN/A
OCF growth 5YN/A